SOLICITATION NOTICE
A -- 2018 NIAID Omnibus Broad Agency Announcement
- Notice Date
- 6/1/2018
- Notice Type
- Presolicitation
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy & Infectious Diseases/AMOB, 5601 Fishers Lane, 3rd Floor MSC 9822, Bethesda, Maryland, 20892, United States
- ZIP Code
- 20892
- Solicitation Number
- HHS-NIH-NIAID-BAA2018-1
- Point of Contact
- Julie Catherine Rodriguez, Phone: 3014022284, George W. Kennedy, Phone: 2406695170
- E-Mail Address
-
julie.rodriguez@nih.gov, kennedyg@mail.nih.gov
(julie.rodriguez@nih.gov, kennedyg@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- NIAID OMNIBUS BROAD AGENCY ANNOUNCEMENT No. HHS-NIH-NIAID-BAA2018-1 1. This broad agency announcement (BAA) will be available ONLY via electronic means. Printed copies of the announcement will not be distributed. Potential offerors are encouraged to refer frequently to the GPE for updates on the program. Any updates or corrections to the announcement will be posted there. The BAA is governed by Federal Acquisition Regulation (FAR) 6.102(d)(2) and FAR 35.016, as well as the NIH Policy Manual, Manual Chapter 6035, Broad Agency Announcements. A BAA may be used as a solicitation mechanism for basic and applied research directed toward advancing the state-of-the-art or increasing knowledge or understanding and that part of development not related to the development of a specific system or hardware procurement. BAAs are general in nature, identifying areas of research interest, and shall only be used when meaningful proposals with varying technical/scientific approaches can be reasonably anticipated. Offers submitted in response to this BAA will be required to present separate detailed technical and business proposals designed to meet the Technical Objectives described for each Research Area proposed. The Statement of Work (SOW), including the specific technical requirements and performance specifications, shall be developed and proposed by the Offeror, not the Government. Proposals received in the response to this BAA are NOT evaluated against each other since they are not submitted in accordance with a common SOW issued by the Government. Instead, Research and Technical Objectives will be provided in the BAA that describe individual Research Areas in which the Government is interested. Proposals received in response to the BAA will be evaluated in accordance with the Evaluation Factors for Award specified in the announcement. The Government reserves the right to conduct discussions with all, some, one, or none of the proposals received in response to this BAA. If discussions are conducted, the Government reserves the right to suggest modifying, adding or deleting milestones, decision points, research plans, processes, schedules, budget or product. The Government also reserves the right to make awards without discussions. Additionally, the Government reserves the right to accept proposals in their entirety or to select only portions of proposals for award. Multiple awards are anticipated. Selection for award under this BAA will be based upon the evaluation factors, importance to the agency programs, and the availability of funds. 2. The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. This Broad Agency Announcement is soliciting proposals that possess the research and development (R&D) expertise necessary for successfully carrying out research toward meeting the program objectives of the Division of Microbiology and Infectious Diseases (DMID), NIAID, NIH. The Research Areas included in this NIAID OMNIBUS BROAD AGENCY ANNOUNCEMENT No. HHS-NIH-NIAID-BAA2018-1, as well as the projected amounts of available funding, are discussed below. Dates for receipt of proposals are identified separately for EACH Research Area within the solicitation. DIVISION OF MICROBIOLOGY AND INFECTIOUS DISEASES (DMID), NIAID, NIH NIAID estimates that two or more awards may be issued for the Research Areas identified below, for a total estimated funding amount up to $15.5 million for non-severable base contract work across all contracts (direct and indirect costs combined.) The total duration of a proposed contract should be consistent with the nature and complexity of the offeror's proposed research. The total performance period comprised of the base and any options proposed by an Offeror should not exceed five (5) years. Research Area 001: Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases The objective of this Research Area is the development of broad-spectrum therapeutic products for use in post-event settings following the intentional release of select pathogens, or in response to naturally-occurring outbreaks of infectious diseases caused by pathogens identified in this Research Area. Solicited products are anticipated to include: Antibacterial Therapeutics; Antiviral Therapeutics; and, Anti-toxin Therapeutics. Research Area 002: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases The objective of this Research Area is the development of vaccines for scenarios associated with intentional release of a NIAID Category A, B, or C Priority Pathogen, or in response to naturally-occurring outbreaks of infectious diseases caused by these pathogens or Zika virus (Zika virus vaccine would be included only as a component of a multivalent vaccine for other pathogens such as a vaccine for Flavivirus family). Solicited Products are anticipated to include: Technology Gaps that Slow Progression to Clinical Testing; Novel Vaccine "Plug-and-Play" Technologies; Enhanced Vaccine Performance (with special interest in simplicity and speed of delivery, rapid immune response and sterilizing immunity); and Vaccines Against Antimicrobial Resistance Threats. 3. Any responsible offeror may submit a proposal which shall be considered by the Agency. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted. For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by facsimile or e-mail is not acceptable. For directions on using eCPS, go to the website https://ecps.nih.gov/NIAID and then click on "How to Submit."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/AMOB/HHS-NIH-NIAID-BAA2018-1/listing.html)
- Record
- SN04941124-W 20180603/180601230822-6207d04c57a8ff0836387a0137332b16 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |